/General

Theranos, the FDA, and the Laboratory-Developed Test (LDT) loophole

By |2019-02-13T16:57:06-07:00February 13th, 2019|

Cover of Forbes 400 Sept 2015 issue: "The Freshman: Elizabeth Holmes leads the class of 2014" Theranos, the FDA, and the Laboratory-Developed Test (LDT) loophole How could Theranos get away with fraud for such a long time? The American television news broadcaster ABC has produced an excellent six-part audio podcast called “The Dropout” [...]

Optimum plasma sample collection and handling for cell-free DNA liquid biopsies

By |2019-01-28T06:02:21-07:00December 13th, 2018|

Optimum plasma sample collection and handling for cell-free DNA liquid biopsies A recent publication indicates the best way to preserve intact cell-free DNA for any minimally-invasive genomic assay Liquid biopsy, whether examining cell-free DNA or circulating tumor cells (CTCs), is a very promising approach for non-invasive cancer management. In particular, cell-free DNA approaches in plasma [...]

Circulating Biomarkers: the Internet of Biology

By |2019-01-28T14:44:12-07:00October 26th, 2018|

Circulating Biomarkers: the Internet of Biology Signals within the remarkable circulatory system A few weeks ago learning about a new San Diego CA company called Cardea Biosciences they described a novel functionalized graphene biosensor with the tagline, ‘Powering the Internet of Biology’. This is a powerful metaphor – the Internet is seen as a ‘fourth [...]

An Early Mark: Announcing the Singlera Genomics Blog

By |2019-01-28T14:59:21-07:00October 21st, 2018|

An Early Mark: Announcing the Singlera Genomics Blog Singlera Genomics has been established with the most elusive of goals: to detect disease early, through a gene signature that can be as easy as a blood test. Through analysis of circulating methylated DNA markers in the bloodstream rather than specific DNA mutations, the numbers [...]

Good things come to those who sign up for
An Early Mark
Join our email list to get the latest blog posts straight to your inbox
SUBSCRIBE
Give it a try, you can unsubscribe anytime.
close-link